<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03644771</url>
  </required_header>
  <id_info>
    <org_study_id>20150814</org_study_id>
    <nct_id>NCT03644771</nct_id>
  </id_info>
  <brief_title>Experience With H.P. Acthar Gel Treatment of Patients With Nephrotic Syndrome/Proteinuria Due to Various Etiologies and Its Effect on Podocyte Function</brief_title>
  <acronym>Acthar</acronym>
  <official_title>Experience With H.P. Acthar Gel Treatment of Patients With Nephrotic Syndrome/Proteinuria Due to Various Etiologies and Its Effect on Podocyte Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Greater Boston Medical Associates</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Greater Boston Medical Associates</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with proteinuria to start treatment with Acthar and watch a variety of clinical&#xD;
      parameters with a goal of decreasing proteinuria between 50-100% over a period of nine months&#xD;
      with every 3 months increasing the dose of medication until a decrease of either 50- 100 % of&#xD;
      protein excretion is achieved.&#xD;
&#xD;
      In addition addition podocyte function will be assessed monthly by measuring suPar levels,&#xD;
      tnf alpha, podocyte/creatinine levels as well as podocyte function studies.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with proteinuria/nephrotic syndrome with albumin/creatinine ratios of 50 or 24 hour&#xD;
      urine protein of 500mg or greater will receive increasing doses of H.P. Acthar Gel starting&#xD;
      with 20 units weekly or biweekly for 3 months after a one month washout observational period.&#xD;
&#xD;
      The second three month period calls for 40 units biweekly, and the third three month period&#xD;
      uses 80 units biweekly observing if the reduction in proteinuria reaches a goal of 50-100%.&#xD;
&#xD;
      Pre study clinical parameters include Cbc diff, cmp, lipid with ldl, cortisol, acth, 24 hour&#xD;
      urine for creatinine and protein, urine albumin/creatinine ratio, protein/creatinine ratio,&#xD;
      bone density, hgba1c, weight , blood pressure, vital signs, and overall health questionaire.&#xD;
      Monthly cbc, cmp, prot/creat, alb/creat ratios, and one red top tube and one 50cc urine&#xD;
      container to go to MGH Charlestown for basic podocyte studies. The fourth -3 month&#xD;
      observational period will be with tapering to stopping the dose of Acthar and following the&#xD;
      same monthly and the pre study parameters.&#xD;
&#xD;
      A second year of observation will continue checking patients every other month for one year&#xD;
      to determine the length of protein decrement observed in the first year.&#xD;
&#xD;
      The study will conclude after the second year of drug free followup.&#xD;
&#xD;
      Biomarker studies of podocyte function will be done for the full 2 year period.&#xD;
&#xD;
      Final data analysis will conclude after the 2 year period of observation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 25, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>level of proteinuria</measure>
    <time_frame>2 years</time_frame>
    <description>clinical response and basic science data for podocyte function</description>
  </primary_outcome>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Decrease of Proteinuria With H.P. Acthar Gel and Its Effects on Clinical and Podocyte Function</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acthar</intervention_name>
    <description>4 treatment periods of 3 months each with 20 units biweekly, 40 units biweekly, and 80 units biweekly, with a tapering period to no drug for the fourth 3 month period. Then one year f/u.</description>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      one red top tube of blood per month one 50cc urine container per month&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients 18-75 with proteinuria as described.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patients with proteinuria as above. patients with controlled conditions below are&#xD;
             candidates.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  uncontrolled hypertension,diabetes mellitus, congestive heart failure, coronary artery&#xD;
             disease, peripheral vascular disease.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Greater Boston Medical Associates 211 West St.</name>
      <address>
        <city>Milford</city>
        <state>Massachusetts</state>
        <zip>01757</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin L Gelman, MD</last_name>
      <phone>508-473-2022</phone>
      <email>gelman85@aol.com</email>
    </contact>
    <investigator>
      <last_name>Sanja Sever, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>August 22, 2018</study_first_submitted>
  <study_first_submitted_qc>August 22, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 23, 2018</study_first_posted>
  <last_update_submitted>February 4, 2020</last_update_submitted>
  <last_update_submitted_qc>February 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Proteinuria</mesh_term>
    <mesh_term>Nephrotic Syndrome</mesh_term>
    <mesh_term>Nephrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Yes if clinically necessary otherwise at end of study</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

